1 mutagenesis is a key antiviral mechanism of
T-705.
2 oseltamivir (a neuraminidase inhibitor) and
T-705 (
a nonspecific inhibitor of viral polymerases) cou
3 We investigated the mechanism of
T-705 activity against influenza A (H1N1) viruses by app
4 so explain the broad spectrum of activity of
T-705 against viruses of multiple families.
5 The anti-influenza virus activity of
T-705 and T-1105 (3-hydroxy-2-pyrazinecarboxamide; the a
6 Enzymatic assays showed that
T-705 and T-1105 are poor substrates for human HGPRT hav
7 ase did not change the antiviral activity of
T-705 and T-1105.
8 Since conversion of
T-705 by HGPRT appears to be inefficient, T-705-RMP prod
9 One of these,
T-705 (
favipiravir), has a mechanism of action that is n
10 ed the therapeutic potential of favipiravir (
T-705)
for Lassa fever, both alone and in combination wi
11 Our results demonstrate that
T-705 induces a high rate of mutation that generates a n
12 e phosphoribosyltransferase (HGPRT) converts
T-705 into its ribose-5'-monophosphate (RMP) prior to fo
13 Which enzymes perform the activation of
T-705 is unknown.
14 6-Fluoro-3-hydroxy-2-pyrazinecarboxamide (
T-705)
is a novel antiviral compound with broad activity
15 ys based on cell viability confirmed that no
T-705-
resistant variants were selected.
16 Its active metabolite,
T-705-
ribose-5'-triphosphate (T-705-RTP), is recognized
17 The crystal structure of
T-705-
RMP in complex with human HGPRT showed how this co
18 of T-705 by HGPRT appears to be inefficient,
T-705-
RMP prodrugs may be designed to increase the antiv
19 ve metabolite, T-705-ribose-5'-triphosphate (
T-705-
RTP), is recognized by influenza virus RNA polymer
20 5'-monophosphate (RMP) prior to formation of
T-705-
RTP.
21 In the presence of
T-705,
titers of infectious virus decreased significantl
22 sequencing showed that virus populations in
T-705-
treated mice had greater genetic variability, with
23 We found that
T-705 treatment did not select specific mutations in pot
24 Susceptibility to favipiravir (
T-705)
was assessed using plaque reduction assays.
25 associated with resistance to oseltamivir or
T-705 were detected.